Content Type: Article

  • What Are the Retirement Plan Dollar Limits for 2022?

    What Are the Retirement Plan Dollar Limits for 2022?

    ARTICLE / CLIENT ALERT

    What Are the Retirement Plan Dollar Limits for 2022?

    November 4, 2021

    Read time: 3 min

    Key takeaways
    Overview

    The Secretary of the Treasury announced today the 2022 limits for qualified retirement plans and IRAs based on cost of living increases. The Consumer Price Index for all Urban Consumers is the benchmark used to determine the index. With a cost-of-living increase of 5.9% (the largest cost-of-living increase since 1982), most of the dollar limits are increasing for 2022 as noted in the table on page 2.

    IRS Notice 2021-61 sets forth the annual dollar limitations on benefits and contributions on qualified plans, effective Jan. 1, 2022, as required under Section 415(d) of the Internal Revenue Code. For 2022, the cap on employee deferrals increases to $20,500 and the annual additions limit for 401(k), 403(b) and other defined contribution plans increases to $61,000. Highly compensated employees will have a greater amount of their compensation allocated to a qualified plan with the increase of the compensation cap from $290,000 to $305,000.

    Employers and Plan Sponsors of qualified retirement plans should communicate these limits for 2022 to plan participants. We are available to advise you on updating your enrollment materials, summary plan descriptions, employee handbooks and other employee communications. If you have any questions about the new limits or any other employee benefit matters, please feel free to contact one of the authors.

    Read this Alert.

    Authored by Mark E. Brossman, Ian L. Levin, Ronald E. Richman and Susan E. Bernstein.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    More insights

  • CMS Will Finalize Heightened Penalties, Additional Requirements Under Hospital Price Transparency Rule

    ARTICLE / CLIENT ALERT

    CMS Will Finalize Heightened Penalties, Additional Requirements Under Hospital Price Transparency Rule

    November 3, 2021

    Read time: 3 min

    Key takeaways
    Overview

    On November 2, 2021, the Centers for Medicare and Medicaid Services (CMS) announced that it will implement increased penalties for hospitals that do not comply with the Hospital Price Transparency Rule, effective January 1, 2022. CMS will also finalize several additional requirements for hospitals, including a requirement that hospitals ensure standard charge information is accessible to automated searches and direct downloads.

    CMS will implement a sliding penalty scale based on the hospital’s number of beds. Hospitals with 30 or fewer beds will face a maximum daily penalty of $300, while hospitals with between 31 and 550 beds will face a maximum daily penalty of $10 per bed. Hospitals with more than 550 beds will face a maximum daily penalty of $5,500.

    CMS will also require hospitals to ensure that their standard charge information is easily accessible, without barriers, including but not limited to ensuring that the information is accessible to automated searches and direct file downloads through a link posted on a publicly available website. This requirement will prohibit a single hospital from using multiple machine-readable files, using “blocking codes” or CAPTCHA, or requiring users to agree to terms and conditions or submit other information prior to access.

    CMS also clarified that price estimator tools must allow healthcare consumers, at the time they use the tool, to obtain an estimate of the amount they will be obligated to pay the hospital for a shoppable service. Such estimator tools must be “tailored to individuals’ circumstances (whether an individual is paying out of pocket or using insurance) and provide real-time individualized out of pocket estimates that combine hospital standard charge information with the individual’s benefit information . . . or provide the self-pay amount.” The estimated amount must be “personalized” and reflect a single out-of-pocket dollar amount. An estimated range, by itself, would not meet the regulation’s requirements.

    For more information on these proposed changes, click here.

    In depth
    Authors

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights

  • What Makes the Crowdworker an Employee?

    What Makes the Crowdworker an Employee?

    ARTICLE

    What Makes the Crowdworker an Employee?

    November 2021

    Read time: 2 min

    Key takeaways
    Overview

    Dr. Sandra Urban-Crell and Dr. Thomas Gennert comment in their article on the decision of the Federal Labor Court. The court has dealt with the status of so-called crowdworkers and comes to the conclusion: crowdworkers can be employees.

    In depth
    Authors

    Dr. Thomas Gennert

    Partner

    Düsseldorf

    More insights

  • Agencies Clarify How Employers Can Charge COVID-19 Vaccine Premium Incentives

    Agencies Clarify How Employers Can Charge COVID-19 Vaccine Premium Incentives

    ARTICLE / CLIENT ALERT

    Agencies Clarify How Employers Can Charge COVID-19 Vaccine Premium Incentives

    November 1, 2021

    Read time: 6 min

    Key takeaways
    Overview

    On October 4, 2021, the US Departments of Labor, Treasury, and Health and Human Services (the Tri-Agencies) issued guidance regarding the application of the Health Insurance Portability and Accountability Act (HIPAA) wellness rules to vaccine-related premium surcharges and discounts, clarifying that employers may charge vaccine premium incentives if they adhere to the requirements of activity-only health-contingent programs.

    Employers have grown more interested in exploring incentives designed to increase COVID-19 vaccination rates among employees. Some employers have announced plans to charge unvaccinated employees higher contributions for health coverage than vaccinated employees, while some have been considering other options, such as excluding coverage for COVID-related illnesses, charging higher cost-sharing for COVID-19-related illnesses and offering more generous plan options to employees who are vaccinated.

    In depth

    OCTOBER 2021 TRI-AGENCY GUIDANCE

    HIPAA generally prohibits a group health plan from discriminating among similarly situated individuals based on a health factor. However, there is an exception for “wellness programs.” The Tri-Agencies have distinguished between two types of wellness programs in prior guidance: participatory and health-contingent wellness programs.

    • A program is considered “participatory” if none of the conditions for obtaining a reward under the program are based on an individual satisfying a standard related to a health factor.
    • A program is considered “health-contingent” if it requires an individual to satisfy a standard related to a health factor to obtain a reward (or requires an individual to undertake more than a similarly situated individual based on a health factor in order to obtain the same reward). Health-contingent programs are broken down into two types of programs: activity-only and outcome-based.

    No maximum dollar limits apply to participatory wellness programs; however, health-contingent wellness programs are subject to a 30% incentive limit (i.e., the reward cannot exceed 30% of the cost of coverage, which may go up to 50% when including tobacco-cessation programs). The wellness program also must provide a reasonable alternative standard (RAS) to employees in certain circumstances (i.e., if it is unreasonably difficult for the individual to meet the standard due to a medical condition, or if it is medically inadvisable for the individual to attempt to satisfy the standard). Some employers hypothesized that the premium surcharge on unvaccinated plan participants was a participatory wellness program. The Tri-Agencies disagreed.

    1. Premium Surcharge/Discount

    In the new guidance, the Tri-Agencies take the position that vaccine premium incentive programs are activity-only health-contingent programs. The Tri-Agencies indicate that receipt of the vaccine is a “health factor” that triggers the more restrictive conditions in order to meet the HIPAA exception.

    Thus, the Tri-Agencies provide that a vaccine premium incentive can be permissible under HIPAA, but only if it complies with the five criteria in the HIPAA wellness regulations. The criteria include (among other things) that:

    • The program is reasonably designed to promote health or prevent disease. (In an example in the new guidance, the employer provided a toll-free hotline to answer questions about the vaccine and provide assistance with scheduling appointments.)
    • A reasonable alternative must be provided to obtain the reward for those for whom it is unreasonably difficult due to a medical condition or medically inadvisable to receive the COVID-19 vaccine. (In an example in the new guidance, the reasonable alternative is requiring the individual to provide an attestation that the individual will follow the Centers for Disease Control and Prevention (CDC) masking guidelines for unvaccinated individuals.)
    • The reward (when added to all other wellness incentives for health-contingent programs) must not exceed 30% of the total cost of employee-only coverage (or, if a dependent also can earn the incentive, the cost of the coverage in which the employee and dependent are enrolled).

    Note that the HIPAA wellness rules allow the plan to require a doctor’s note related to whether the COVID-19 vaccine is medically inadvisable.

    2. Denial of Benefits or Coverage

    The new guidance provides that conditioning eligibility for benefits or coverage for otherwise covered items or services (including to treat COVID-19) on participants being vaccinated is not permissible under HIPAA, since it would be discriminatory against these participants based on a health factor and the exception for wellness programs would not apply.

    3. Impact on Employer Mandate Affordability

    The new guidance from the Tri-Agencies addresses how COVID-19 vaccine premium incentives impact affordability of an offer of employer-sponsored coverage for purposes of the Affordable Care Act (ACA) employer mandate. Similar to other non-tobacco premium incentives, vaccine incentives increase the cost of coverage for employer mandate purposes. This means that if the incentive is a premium discount, the discount is treated as not earned; thus, ACA affordability is based on the assumed increased premium cost for the participant. Similarly, if the incentive is a premium surcharge, the surcharge is treated as applying to everyone; thus, affordability is based on the assumed increased premium cost.

    PRIOR EEOC ADA AND GINA GUIDANCE

    The US Equal Employment Opportunity Commission (EEOC) has issued a series of FAQs on when employers can request or require COVID-19 testing or vaccines. The EEOC’s May 2021 FAQs provide that the ADA wellness rules do not apply where the employer merely requests proof of COVID-19 vaccination because that does not constitute a medical exam or a disability-related inquiry. However, an employer still must provide a reasonable accommodation to an employee who cannot get the vaccine due to a disability (or, under Title VII, because of a religious belief). But, if the employer is instead administering the vaccine directly or through an agent, the pre-screening questions constitute a disability-related inquiry subject to the ADA. In that case, incentives are only permitted if they are not so substantial as to be “coercive.”

    With respect to the Genetic Information Nondiscrimination Act (GINA), the EEOC FAQs provide that an incentive for a family member getting vaccinated is generally permissible and no incentive limits apply, as long as the family member gets the vaccine from a third party and not the employer or its agent. An employer is not permitted to give an incentive to an employee for a family member getting the vaccine from the employer or its agent.

    PRACTICAL APPLICATION

    The new guidance from the Tri-Agencies answers a commonly asked question for employers, clarifying that they may charge vaccine premium incentives if they treat them as activity-only health-contingent programs. Employers and group health plan sponsors considering implementing vaccine premium incentives should ensure that they comply with all of the criteria for activity-only health-contingent programs in the HIPAA wellness regulations and account for vaccine premiums in their ACA affordability calculations.

    For more information on whether and how to apply vaccine incentives to your group health plan, please contact your regular McDermott employee benefits lawyer or one of the authors.

    Authors

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • The Build Back Better Act: Tax Reform Implications for Private Equity M&A

    The Build Back Better Act: Tax Reform Implications for Private Equity M&A

    ARTICLE / CLIENT ALERT

    The Build Back Better Act: Tax Reform Implications for Private Equity M&A

    November 1, 2021

    Read time: 7 min

    Key takeaways
    Overview

    On October 28, 2021, US President Joe Biden unveiled his slimmed down $1.75 trillion infrastructure spending plan and congressional leadership released H.R. 5376 (the Build Back Better Act (BBBA)), which contains revised proposals for tax law changes to pay for the various pieces of President Biden’s new agenda. The BBBA follows a set of proposals released by the House Ways and Means Committee on September 14, 2021 (W&M Proposal), and while it incorporates some of the W&M Proposal’s tax law changes, there are notable differences (including wholesale absences of certain changes from the W&M Proposal). Following is a brief summary of certain BBBA concepts which, if enacted in its current form, would potentially increase the overall tax burden on certain parties involved in private equity mergers and acquisitions (M&A) transactions and may have year-end planning implications as a result.

    In depth

    THE GOOD: NO BASE TAX RATE INCREASES, NO CARRIED INTEREST REFORM

    • No Change in Rates: The W&M Proposal includes increases to the top individual and corporate rates, including a five percentage point increase in the rate applicable to long-term capital gains and qualified dividends. The BBBA drops any base tax rate increases on individuals and corporations, including any change to long-term capital gains rates. However, as discussed further below, this does not necessarily mean that parties engaged in M&A transactions will be free from materially higher tax bills resulting from such transactions closing next year.
    • No Carried Interest Changes: The BBBA scraps the W&M Proposal’s increase in the holding period (to five years) applicable for carried interests to qualify for long-term capital gains rates. Thus, the existing three-year holding period (and related statutory structure of Section 1061 as originally enacted under the Tax Cuts and Jobs Act) would remain the same. There are no other explicit proposals that address carried interest arrangements, so fund managers can rest easier now that their incentive structures are, at least for the moment, no longer the subject of an attack.
    • No Income Limitation for Section 199A Deduction: While the W&M Proposal sought to limit the application of the 20% deduction for “qualified business income” of non-corporate taxpayers under Section 199A of the Code, the BBBA drops this proposal. As a result, the “high income” caps previously proposed that could impact high-income partners of a partnership or shareholders of an S corporation are no longer on the table.

    THE BAD: 3.8% MEDICARE TAX STILL APPLIES MORE BROADLY AND OTHER UNFAVORABLE CHANGES FOR SMALL BUSINESSES

    • Net Investment Income Tax Expansion: The BBBA largely adopts without change the W&M Proposal’s expansion of the 3.8% net investment income tax starting in 2022. The proposal eliminates a perceived “loophole” by subjecting all trade or business income of individuals with earnings over $400,000 (individual) or $500,000 (married couples) to the 3.8% net investment income tax—except to the extent already subject to self-employment tax. This is an unfavorable change for owners of limited partnerships or S corporations who “materially participate” in the business and were not previously subject to the 3.8% tax or self-employment tax (other than self-employment tax on S corporation owners’ “reasonable compensation” as an employee) and, as noted below, in particular upon a sale transaction.
    • Reduction in QSBS Benefits: The BBBA would also retain the W&M Proposal’s changes to materially limit the benefits for owners of “qualified small business stock” (QSBS). The BBBA would reduce the 100% gain exclusion (in place since 2010) for any sales or exchanges of QSBS occurring after September 13, 2021, to 50% (unless a binding contract was entered into as of that date and is not subsequently modified in any material respect). Individual taxpayers with adjusted gross incomes of less than $400,000 would, however, continue to be entitled to the 100% exclusion. As with the W&M Proposal, there are no grandfathering rules for owners of QSBS as of the proposed effective date. Thus, all high-income current and future investors in QSBS will only be entitled to a reduced 50% gain exclusion on future sales and exchanges, significantly impacting the anticipated tax benefits of investing in such businesses.
    • No Free S Corp Exit: The BBBA drops a provision from the W&M Proposal that would have given qualifying S corporations a limited window to reorganize into a partnership tax free. The original proposal was narrowly drafted but as with many aspects of the BBBA, there is no free lunch here.

    THE UGLY: 5 – 8% SURCHARGE ON HIGH INCOME TAXPAYERS AND 15% MINIMUM TAX ON LARGE CORPORATIONS

    • Surcharge on High-Income Taxpayers: The BBBA would impose new “surcharges” on individuals, estates and trusts with modified adjusted gross income (MAGI) in excess of certain thresholds. These additional taxes would apply for taxable years beginning after December 31, 2021. The surcharge is either 5% or 8% (e., the initial 5% plus an additional 3%) on the taxpayer’s income in excess of the applicable thresholds set forth in the table below. This surcharge would apply to many family or founder sellers in private equity M&A transactions.
    5% Surcharge 8% Surcharge
    Individuals[1] $10,000,000 $25,000,000
    Estates or Trusts $200,000 $500,000
    • Corporate Profits Minimum Tax: The BBBA would introduce a new Corporate Profits Minimum Tax, which would impose a 15% minimum tax on the book profits of corporations (other than S corporations, regulated investment companies and real estate investment trusts) that report an average of more than $1 billion of adjusted financial statement income over a three-year period. For this purpose, a taxpayer’s financial statement would include a financial statement on a Form 10-K filed with the US Securities and Exchange Commission (SEC) and, in the absence of such a financial statement, a financial statement used for a substantial non-tax purposes. The $1 billion threshold is determined after aggregating certain corporations under common ownership or control, such that the minimum tax may apply to corporations other than large multinationals (such as portfolio companies of private equity funds). The Corporate Profits Minimum Tax would apply to taxable years beginning after December 31, 2022.

    YEAR-END PLANNING IMPLICATIONS FOR PRIVATE EQUITY M&A TRANSACTIONS

    Several changes included in the W&M Proposal that would have adversely affected parties in common private equity M&A transactions are noticeably absent from the BBBA. Nevertheless, if the BBBA were enacted as proposed, such taxpayers would not escape unscathed. Of particular importance for sellers, the surcharge on income in excess of the applicable thresholds coupled with the expansion of the 3.8% net investment income tax to apply to gain from the sale of limited partnerships or S corporations could increase the tax liability on a portion of the gain recognized for transactions that close during 2022 or later by as much as 11.8 percentage points compared with those that close before year-end. However, for transactions where a 2021 closing is not feasible, parties might consider engaging in certain pre-closing restructuring transactions designed to accelerate gain recognition to the 2021 tax year. Sellers who would otherwise have income below the surcharge thresholds but for taxable income arising from a sale transaction may also consider structuring transactions as installment sales in order to spread the gain from the sale across two or more years in order avoid the surcharge tax.

    [1] For a married individual filing a separate return, the 5% surcharge applies to the individual’s MAGI in excess of $5,000,000 and the 8% surcharge applies to the individual’s MAGI in excess of $12,500,000.

    Authors

    Kevin Hall

    Partner

    Miami

    Alejandro Ruiz

    Partner

    San Francisco

    More insights

  • FDA Issues Good Machine Learning Practice Guiding Principles

    ARTICLE / CLIENT ALERT

    FDA Issues Good Machine Learning Practice Guiding Principles

    October 29, 2021

    Read time: 6 min

    Key takeaways
    Overview

    On October 27, 2021, pursuant to the Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan (Action Plan), the US Food and Drug Administration (FDA) released its Good Machine Learning Practice for Medical Device Development: Guiding Principles (Guiding Principles) developed in conjunction with Health Canada and the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). In the Action Plan, FDA noted that stakeholders had called for FDA to encourage harmonization of the development of good machine learning practices (GMLP) through consensus standards efforts and other community initiatives. GMLP are AI/ML best practices (e.g., data management, feature extraction, training and evaluation) that are analogous to quality system practices or good software engineering practices.

    In depth

    FDA also solicited feedback from stakeholders on GMLP in its 2019 Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Discussion Paper and Request for Feedback. The 10 guiding principles, while not formal or binding, provide a helpful framework for developers and identify areas where collaborative bodies and international standards organizations could work to advance GMLP through the development of formal policies and guidance.

    Guiding Principles

    1. Leveraging Multi-Disciplinary Expertise Throughout the Total Product Life Cycle
      Having an in-depth understanding of how the ML-enabled medical device will be integrated into the clinical workflow can help ensure that such devices are safe and effective. Developers should rethink the traditional device development process to include inputs from internal stakeholders such as the chief information security officer, privacy and data strategy personnel, and medical personnel. Input from these stakeholders may be needed earlier in the design and development process than is typical for traditional devices.
    2. Implementing Good Software Engineering, Data Quality Assurance, Data Management and Security Practices
      These practices include methodical risk management and design process designed to capture and communicate design, implementation and risk management decisions and rationale, and to ensure data authenticity and integrity. Developers should also consider FDA’s Content of Premarket Submissions for Management of Cybersecurity in Medical Devices guidance and interoperability of ML-enabled devices within systems or workflows from different manufacturers.
    3. Designing Clinical Studies with Participants and Data Sets That Are Representative of the Intended Patient Population
      Consistent with FDA’s Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry (discussed in depth here), data collection protocols should ensure that relevant characteristics of the intended patient population, use and measurement inputs are sufficiently represented in a sample of adequate size in the clinical study or training and test datasets. This allows results and use of data to be generalizable and helps mitigate bias.
    4. Ensuring Training Data Sets Are Independent of Test Sets
      Developers should consider sources of dependence (e.g., patient, data acquisition and site factors) and ensure that training datasets and test datasets are appropriately independent of one another. This principle suggests that regulators will expect developers to explain how they separated the training and test sets to control for bias and confounding factors.
    5. Ensuring Selected Reference Datasets Are Based Upon Best Available Methods
      Developers should use the best available, accepted methods for developing a reference standard to ensure they collect clinically relevant and well-characterized data, and should ensure that they understand the limitations of the reference. Where available, developers should use accepted reference datasets in model development and testing. This may present a hurdle for ML-enabled devices that address disease states or therapeutic areas for which there is no single universally accepted reference standard.
    6. Tailoring Model Design to the Available Data and Reflecting the Intended Use of the Device
      Model design should be suited to the available data and actively mitigate against known risks (e.g., overfitting, performance degradation, security risks). The Guiding Principles suggest that the regulators may expect developers to provide more detailed information to demonstrate alignment between a product’s proposed intended use and indications for use and the design of the model in terms of mitigating risks and demonstrating efficacy and performance.
    7. Placing Focus on the Performance of the Human-AI Team
      To the extent the model has a human element, developers should consider human factors and interpretability of model outputs. Considerations that inform traditional device development, such as the impact of human factors, the need for specialized training to use the device, and the expected effect on clinical outcomes (i.e., improvements) and impact on clinical and other user work flows, will be equally important for machine-learning tools.
    8. Demonstrating Device Performance by Testing During Clinically Relevant Conditions
      Device performance should be evaluated independently of the training data set. Testing performance should consider the intended patient population, clinical environment, human users, measurement inputs and potential confounding factors.
    9. Providing Users With Clear, Essential Information
      Users should be provided with clear, contextually relevant information, including the product’s intended use and indications for use, information about the model’s performance in relevant subgroups, characteristics of the data used to train and test the model, acceptable inputs, known limitations, how to interpret the user interface and how the model integrates into the clinical workflow. Users also should be apprised of device modifications, updates from real-world performance monitoring, the basis for decision-making, and a way to communicate product concerns to the developers.
    10. Monitoring Deployed Models for Performance and Ensuring Retraining Risks are Managed
      Developers should monitor deployed models. Additionally, when models are trained after deployment, whether continually or periodically, developers should ensure that there are appropriate controls to manage risks of overfitting, unintended bias or degradation of the model (e.g., dataset rift) that could impact the safety or performance of the deployed model. Developers also should consider how to ensure that the datasets they use to develop and train models will not become stale or outdated over time. The Guiding Principles suggest that regulators will expect developers to consider how changes to real-world clinical assumptions, diagnosis or treatment standards may impact the tool’s performance over its expected lifecycle.

    Although the Guiding Principles provide practical, common-sense principles for GMLP, the concepts are not necessarily new. The more challenging task for the regulators and for industry will be developing concrete practices, policies and procedures for ML tools within or alongside the existing framework for medical device quality system regulation in the United States, UK, European Union and other regions.

    The Guiding Principles docket, FDA-2019-N-1185, is open for public comment. FDA recently announced that it plans to publish a draft guidance on Marketing Submission Recommendations for A Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions, as development resources in permit, in current Fiscal Year 2022.

    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • US Deputy Attorney General Signals Aggressive DOJ Focus on Corporate Crime

    US Deputy Attorney General Signals Aggressive DOJ Focus on Corporate Crime

    ARTICLE / CLIENT ALERT

    US Deputy Attorney General Signals Aggressive DOJ Focus on Corporate Crime

    October 29, 2021

    Read time: 9 min

    Key takeaways
    Overview

    At an October 28, 2021, speech before the American Bar Association’s Annual National Institute on White Collar Crime, US Deputy Attorney General (Deputy AG) Lisa Monaco re-emphasized the priority placed by current leadership within the US Department of Justice (DOJ) on prosecuting white-collar crime at both the individual and corporate level. Deputy AG Monaco also announced three new actions that DOJ will be taking—effective immediately—to strengthen the way DOJ responds to corporate crime.

    While Deputy AG Monaco emphasized that DOJ will continue to focus on individual accountability in white-collar criminal investigations and prosecutions, all of the changes announced focus on the manner in which corporations will be expected to behave—and will be evaluated—in the context of a DOJ investigation.

    • First, to be eligible for any cooperation credit, corporations will now be required to provide DOJ “with all non-privileged information about individuals involved in or responsible for the misconduct at issue.” It will no longer be sufficient for companies to limit such disclosures to those individuals who were “substantially involved” in the misconduct.
    • Second, in evaluating a corporate resolution, prosecutors are now directed to consider “the full range” of prior state or federal “criminal, civil and regulatory” misconduct by a company, rather than limiting such consideration to misconduct of the same type or that is factually related to the misconduct at issue.
    • Third, corporations will once again be regularly subject to the prospect of independent monitorships as part of corporate resolutions. Prosecutors will be free to require monitorships as a condition of resolutions “whenever it is appropriate to do so to satisfy [DOJ] that a company is living up to its compliance and disclosure obligations.”

    Taken collectively, the newly announced actions suggest that DOJ will be aggressive in pursuing corporations and underscore the need for companies to “actively review their compliance programs to ensure they adequately monitor for and remediate misconduct.”

    In depth

    DOJ’s Principles of Federal Prosecution of Business Organizations (Principles), first promulgated in 1999 and amended multiple times since, provide the framework by which the conduct of a corporation—including its efforts to cooperate with a federal criminal investigation—are evaluated. Those Principles include guidance on how a corporation’s “past history,” “compliance programs” and efforts at cooperation are assessed, and they provide parameters on the nature and scope of information that a corporation may be required to provide to earn cooperation credit.

    While both the Principles themselves and Deputy AG Monaco’s October 28 remarks emphasize DOJ’s focus on individual wrongdoers and “individual accountability,” the new guidance focuses exclusively on how corporations will be evaluated by DOJ in the context of ongoing criminal investigations.

    In particular, and in addition to a promised “surge of resources” to help prosecutors investigate and prosecute white-collar crime, Deputy AG Monaco announced three changes to the Principles effective immediately that collectively have the potential to impose substantial new burdens on corporations and create heightened risk of increased penalties and oversight.

    1. Companies Must Now Provide Information on All Individuals Involved in the Conduct at Issue

    To be eligible for any cooperation credit, corporations will now be required to provide DOJ “with all non-privileged information” about “all individuals involved in the misconduct, regardless of their position, status or seniority.” It will no longer be sufficient for companies to provide information related to those individuals who were “substantially involved” in the conduct at issue. Corporations and their counsel will thus no longer have discretion to draw distinctions based on the magnitude, significance or scope of an employee’s conduct or withhold information about modest or peripheral participants in the conduct under investigation.

    As a practical matter, this means that corporations should expect DOJ to heavily scrutinize any disclosures made to the government during a corporate investigation. While prosecutors are not permitted to demand privileged information, they are still more likely to press corporate counsel for additional information, particularly as to the scope of any internal investigation or the identities of employees believed to have knowledge of the alleged misconduct at issue. Prosecutors may also threaten to withhold cooperation credit if they feel that a company has failed to disclose sufficient information regarding any potential wrongdoers or witnesses.

    2. Prosecutors Must Now Consider Any Prior Criminal, Civil or Regulatory Issue

    In evaluating a corporate resolution, prosecutors will now be directed to consider “the full range” of prior state or federal “criminal, civil and regulatory” misconduct by a company, rather than limiting such consideration to misconduct of the same type or that is factually related to the misconduct at issue. When evaluating a company in the context of a Foreign Corrupt Practices Act (FCPA) investigation, for example, DOJ will no longer focus principally on the company’s prior FCPA compliance but will instead look at any prior federal, state or local criminal, civil or regulatory matters the company may have faced and will “assume[] all prior misconduct is potentially relevant.”

    As a result, companies with any prior civil, criminal or regulatory issues—however minor or seemingly unrelated to the alleged misconduct at issue—will now likely face increased obstacles, particularly when seeking or negotiating non-prosecution or deferred-prosecution agreements. DOJ’s focus on “repeat offenders” will present particular risks for corporations operating in heavily regulated industries—such as healthcare, finance and energy—where prior regulatory actions may now present obstacles to resolving seemingly unrelated criminal investigations.

    For example, DOJ may now look at a healthcare company’s prior dealings with the US Department of Health and Human Services in addressing an unrelated matter when evaluating the fine or penalty to be imposed in resolving a criminal tax investigation. Prosecutors could also look to a financial institution’s prior resolution of a matter with the US Department of the Treasury (or even a state regulator) in determining how to resolve an unrelated criminal FCPA investigation.

    Such prior, unrelated civil, criminal or regulatory matters may not only impact the fines and penalties imposed by DOJ in reaching a criminal resolution, but they may also determine the type of resolution DOJ is willing to offer, or, as discussed below, inform DOJ’s decision to require the imposition of a monitor.

    3. Monitorships May Be Imposed More Frequently

    Corporations will once again be subject to the prospect of independent monitorships as part of corporate resolutions. Citing a shift from the 2018 announcement by then-head of the Criminal Division Brian Benczkowski that “the imposition of a monitor will not be necessary in many criminal resolutions”—and what Deputy AG Monaco described as a sense that “monitorships are disfavored or the exception”—prosecutors will now be free to require monitorships as a condition of resolutions “whenever it is appropriate to do so to satisfy [DOJ] that a company is living up to its compliance and disclosure obligations.”

    This is a significant change. Companies will again face the prospect of the scrutiny and expense associated with the imposition of corporate monitorships, which are almost certain to increase in 2022 after several years in which numerous high-profile corporate resolutions did not require imposition of a monitor. For example, in the context of FCPA resolutions, despite record-setting fines and penalties in 2020, not a single monitorship was imposed as part of any resolution (down from nine monitorships imposed as part of FCPA resolutions in 2016). More broadly, no other monitorships were imposed by other units of DOJ’s Fraud Section in 2020, and just one has been imposed in 2021 by the Market Integrity and Major Frauds Unit. Deputy AG Monaco made clear she expects that monitorships will be imposed much more routinely.

    KEY TAKEAWAYS

    First, Deputy AG Monaco’s remarks confirm that corporations and their executives should expect increased DOJ enforcement activity in the white-collar space. Among other things, Monaco noted that DOJ will be “surging resources” to DOJ prosecutors to assist with complex corporate investigations and referenced DOJ’s ongoing and increased use of sophisticated data analytics to investigate and prosecute corporate wrongdoing. Deputy AG Monaco also announced the formation of the “Corporate Crime Advisory Group,” which will provide recommendations regarding additional resources to “assist more rigorous enforcement.”

    Second, the need for corporations to actively review compliance programs to ensure they are appropriate to the company’s risk profile and adequate to ensure ongoing compliance has never been greater. Deputy AG Monaco specifically directed companies to undertake such reviews, adding that a failure to do so would “cost them down the line.” She further emphasized the importance of effective corporate compliance programs and warned that DOJ “will ensure that the absence of such programs inevitably proves a costly omission for companies who end up the focus of department investigations.”

    Third, companies with any history of regulatory misconduct will need to be particularly cautious as such misconduct—however minor or unrelated to the matter at hand—may now be considered by DOJ should a new issue arise. In particular, such companies may now be subjected to increased DOJ scrutiny, and they may similarly face additional challenges in negotiating a corporate resolution.

    Companies should consider taking a number of immediate steps to respond to these significant updates. Companies should proactively assess whether their compliance programs are appropriately designed to address significant areas of risk and whether those programs are operating as intended in practice. Companies should take particular account of any recent litigation, investigation or regulatory matter (as well as their ongoing compliance with any recent resolution of such matter) or ongoing agreement with any state or federal regulator. Finally, companies should also consider whether any ongoing internal investigations need to be adjusted in scope to ensure they are capturing information that DOJ now expects to receive in order to receive cooperation credit.

    Authors

    Edward B. Diskant

    Partner

    New York – One Vanderbilt Avenue

    Julian L. André

    Partner

    Los Angeles

    Benton Curtis

    Partner

    Miami

    Paul M. Thompson

    Partner

    Washington, DC

    More insights

  • First Details Leaked Regarding OSHA’s Vax-or-Test Rule

    First Details Leaked Regarding OSHA’s Vax-or-Test Rule

    ARTICLE / CLIENT ALERT

    First Details Leaked Regarding OSHA’s Vax-or-Test Rule

    October 29, 2021

    Read time: 4 min

    Key takeaways
    Overview

    UPDATE (12/22/2021):

    As of December 15, 2021, the CMS IFR has been reinstated in 25 states. As of December 17, 2021, the OSHA “vax or test” ETS has been reinstated nationwide, with enforcement dates beginning in January 2022. The federal contractor mandate remains under a nationwide stay, with no enforcement currently permitted. Read more here.


    On October 28, 2021, several details were released regarding the US Occupational Safety and Health Administration’s (OSHA) highly anticipated emergency temporary standard (ETS), also known as the “vax-or-test rule.” The ETS, which will apply to employers with at least 100 employees, was sent to the White House on October 12, 2021, for final review and is expected to be published in the first week of November 2021.

    According to leaked information, under the upcoming rule, employers will be permitted to decide to either mandate vaccination for all employees (except those with a legally protected exemption) or allow unvaccinated employees to opt for testing and masking.

    If employees are able to be vaccinated but choose the “test and mask” option (under their employer’s policy), OSHA’s rule will allow employers to require employees to pay for their own tests and masks.

    Sources noted, however, that if an employee has a legally protected reason that precludes vaccination, such as a medical condition or a sincerely held religious belief, the employer will be required to cover the cost of testing and masking supplies.

    Regardless of the reason for remaining unvaccinated, it appears that all unvaccinated employees will be required to wear masks while indoors and when in close contact with coworkers.

    It is currently unclear how exactly OSHA’s testing payment requirements will interplay with state and local laws that require employers to compensate employees for time spent “working,” as well as state and local laws governing reimbursement of necessary business expenses.

    OSHA is expected to provide employers with a reasonable period to develop and implement policies in compliance with the upcoming rule before enforcement begins. Citations could amount to as much as $14,000 per violation.

    OSHA’s ETS has yet to be finalized and details are subject to change. McDermott is keeping up with the latest developments as they become available.

    In depth

    On October 28, 2021, several details were released regarding the US Occupational Safety and Health Administration’s (OSHA) highly anticipated emergency temporary standard (ETS), also known as the “vax-or-test rule.” The ETS, which will apply to employers with at least 100 employees, was sent to the White House on October 12, 2021, for final review and is expected to be published in the first week of November 2021.

    According to leaked information, under the upcoming rule, employers will be permitted to decide to either mandate vaccination for all employees (except those with a legally protected exemption) or allow unvaccinated employees to opt for testing and masking.

    If employees are able to be vaccinated but choose the “test and mask” option (under their employer’s policy), OSHA’s rule will allow employers to require employees to pay for their own tests and masks.

    Sources noted, however, that if an employee has a legally protected reason that precludes vaccination, such as a medical condition or a sincerely held religious belief, the employer will be required to cover the cost of testing and masking supplies.

    Regardless of the reason for remaining unvaccinated, it appears that all unvaccinated employees will be required to wear masks while indoors and when in close contact with coworkers.

    It is currently unclear how exactly OSHA’s testing payment requirements will interplay with state and local laws that require employers to compensate employees for time spent “working,” as well as state and local laws governing reimbursement of necessary business expenses.

    OSHA is expected to provide employers with a reasonable period to develop and implement policies in compliance with the upcoming rule before enforcement begins. Citations could amount to as much as $14,000 per violation.

    OSHA’s ETS has yet to be finalized and details are subject to change. McDermott is keeping up with the latest developments as they become available.

    Authors

    Abigail M. Kagan

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • The Final Code Sec. 267A Regulations and Payments by CFCs

    The Final Code Sec. 267A Regulations and Payments by CFCs

    ARTICLE

    The Final Code Sec. 267A Regulations and Payments by CFCs

    September-October 2021

    Read time: 2 min

    Key takeaways
    Overview

    Jonathan Lockhart, and David Noren authored this bylined article on Code Sec. 267A regulations and the careful consideration that should be taken into account when planning hybrid financing or licensing arrangements with CFCs.

    In depth
    Authors

    David G. Noren

    Partner

    Washington, DC

    More insights

  • Antitrust M&A Snapshot | Q3 2021

    Antitrust M&A Snapshot | Q3 2021

    ARTICLE / REPORT

    Antitrust M&A Snapshot | Q3 2021

    October 28, 2021

    Read time: 3 min

    Overview

    JULY – SEPTEMBER 2021: HIGHLIGHTS

    UNTIED STATES:

    • The US Department of Justice’s (DOJ) challenge of American Airlines and JetBlue’s “Northeast Alliance” after the joint venture’s approval by the US Department of Transportation earlier this year demonstrates the Biden administration’s commitment to aggressive antitrust enforcement.
    • US President Joe Biden issued an Executive Order calling for tougher antitrust enforcement, including “encouraging” the DOJ and Federal Trade Commission (FTC) to modify the horizontal and vertical merger guidelines to address increasing consolidation. At the same time, the FTC, under Chair Lina Khan, continues its rapid pace of change to the merger review process, including introducing Pre-Consummation Warning Letters, rescinding the 2020 Vertical Merger Guidelines, repealing an over 25-year-old policy statement on “prior approval” obligations in merger settlements, and issuing more comprehensive and rigorous procedures for Second Requests. These changes only apply to transactions that the FTC reviews.
    • Aon PLC and Willis Towers Watson abandoned their tie-up following a DOJ challenge, and the FTC successfully obtained a preliminary injunction to prevent Hackensack Meridian Health from acquiring Englewood Healthcare, in major litigation wins for the antitrust agencies.

    EUROPEAN UNION:

    • Under a new interpretation of Article 22 of the EU Merger Regulation (EUMR), the European Commission (Commission) asserted jurisdiction over Illumina’s acquisition of GRAIL and Facebook’s acquisition of Kustomer, even though the transactions did not meet the Commission or Member State filing thresholds.
    • The EU’s Market Definition Notice will focus on innovation and digital markets.
    • The EU General Court confirms a significant gun-jumping fine imposed on Altice for breach of the EUMR notification and standstill obligations.

    UNITED KINGDOM:

    • The Competition & Markets Authority’s (CMA) handling of the Veolia/Suez transaction demonstrates the CMA’s willingness to engage with parties to seek practical interim solutions while it is investigating a consummated transaction for potential antitrust concerns.
    • The UK government published plans to update antitrust rules, including revising its jurisdictional thresholds and expanding the “share of supply” test to allow the CMA to more easily capture vertical and conglomerate mergers, as well as acquisitions of startups.
    • The CMA published its Annual Report 2020. In total, the CMA reviewed 600 transactions, with less than 5% of these prohibited or cleared subject to remedies.
    In depth
    Tabs

    Noah Feldman Greene

    Partner

    Washington, DC

    Max Küttner

    Associate

    Düsseldorf

    Jon B. Dubrow

    Partner

    Washington, DC

    Joel R. Grosberg

    Partner

    Washington, DC

    Lisa P. Rumin

    Partner

    Washington, DC

    More insights
    Endnotes